You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
九强生物(300406.SZ)业绩快报:2020年净利降66.20%至1.12亿元
格隆汇 03-25 15:41

格隆汇 3 月 25日丨九强生物(300406.SZ)披露2020年度业绩快报,2020年实现营业收入8.48亿元,同比增长0.86%;营业利润为1.54亿元,同比下降59.32%;利润总额为1.38亿元,同比下降63.98%;归属于母公司普通股东的净利润为1.12亿元,同比下降66.20%;基本每股收益0.21元。

报告期内,由于全国各地受国外疫情输入和本土疫情反弹的影响,医疗机构正常的诊疗工作受到一定限制,生化诊断试剂终端需求受到一定影响,疫情期间,公司原材料采购、生产安排、物流配送受到一定程度限制,生产经营受到一定的影响。与此同时公司不断加大市场开拓力度,拓展销售渠道,寻求新的经济增长点。同时,以市场为导向,进一步加大研发投入,不断创新产品,丰富产品结构。

公司合并范围本期较上期增加福州迈新生物技术开发有限公司及其孙公司、福州戴诺斯医学科技有限公司、福州迈新医学检验所有限公司、Lumatas BioSystems Inc.

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account